Literature DB >> 12569572

PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations.

Tsuyoshi Saito1, Yoshinao Oda, Ken-ichi Kawaguchi, Tomonari Takahira, Hidetaka Yamamoto, Sadafumi Tamiya, Kazuhiro Tanaka, Shuichi Matsuda, Akio Sakamoto, Yukihide Iwamoto, Masazumi Tsuneyoshi.   

Abstract

The tumor suppressor gene PTEN/MMAC1 was identified on chromosome 10q23.3, which is homozygously deleted in many human malignancies. The loss of chromosome 10q was also frequently reported in some types of soft tissue sarcomas. Our study was designed to investigate the frequency of PTEN/MMAC1 gene mutation and to evaluate the role of the PTEN/MMAC1 gene in the tumorigenesis of soft tissue sarcomas without specific balanced translocations. We analyzed 51 cases of soft tissue sarcomas without specific balanced translocations for PTEN/MMAC1 mutations by polymerase chain reaction-single strand conformation polymorphism and direct sequencing. Mutations in the PTEN/MMAC1 gene were found in only 2 cases (3.9%). Both tumors with PTEN/MMAC1 mutation were leiomyosarcomas arising from the retroperitoneum and inferior vena cava, respectively. Two of 3 leiomyosarcomas arising from the intra-abdominal cavity examined harbored mutations of this tumor suppressor gene. This result suggests that leiomyosarcomas derived from the intra-abdominal cavity might have different tumorigenesis from those of an extremity or the trunk, from the viewpoint of PTEN/MMAC1 mutation, although PTEN/MMAC1 gene mutations are rare event in these soft tissue sarcomas. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12569572     DOI: 10.1002/ijc.10918

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

2.  Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

Authors:  Maria V Guijarro; Sonika Dahiya; Laura S Danielson; Miguel F Segura; Frances M Vales-Lara; Silvia Menendez; Dorota Popiolek; Khushbakhat Mittal; Jian Jun Wei; Jiri Zavadil; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Eva Hernando
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307

Review 3.  The role of mTOR inhibitors for treatment of sarcomas.

Authors:  Monica M Mita; Anthony W Tolcher
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

4.  Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.

Authors:  Narasimhan P Agaram; Lei Zhang; Francois LeLoarer; Tarik Silk; Yun-Shao Sung; Sasinya N Scott; Deborah Kuk; Li-Xuan Qin; Michael F Berger; Cristina R Antonescu; Samuel Singer
Journal:  Genes Chromosomes Cancer       Date:  2015-11-06       Impact factor: 5.006

5.  Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma.

Authors:  Allie H Grossmann; Lester J Layfield; R Lor Randall
Journal:  Sarcoma       Date:  2012-02-15

Review 6.  The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.

Authors:  Sioletic Stefano; Scambia Giovanni
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

7.  Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry.

Authors:  Liang Yin; Wei-Juan Cai; Chun-Xia Liu; Yun-Zhao Chen; Jian-Ming Hu; Jin-Fang Jiang; Hong-An Li; Xiao-Bin Cui; Xiang-Yun Chang; Wen Jie Zhang; Kan Sun; Feng Li
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

Review 8.  Targeted therapy for sarcomas.

Authors:  Charles Forscher; Monica Mita; Robert Figlin
Journal:  Biologics       Date:  2014-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.